LearnGlossaryMarketStocksSuperinvestorsSign in

RLYB

Rallybio Corporation

Healthcare · $90M market cap

Verdict

We can't put a fair value on RLYB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-42.0% a year✗
Sales growth34.9% a year✓
Free cash flow growth—?
Return on invested capital-73.3%✗

Follow RLYB

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds RLYB. In Q1 2026, 1 trimmed. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$8.4M

524,347 shares

Moves in Q1 2026

Trimmed: Viking Global Investors

About Rallybio Corporation

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works